Recombinant Human Thyrotropin-Stimulated Radioiodine Therapy in Patients with Multinodular Goiters: A Meta-Analysis of Randomized Controlled Trials
Horm Metab Res DOI: 10.1055/a-1240-5058A potential reduction of goiter volume (GV) of recombinant human thyrotropin
(rhTSH) on multinodular goiters (MNG) was previously reported but controversial.
Hence we conducted a meta-analysis to estimate the effect of rhTSH-stimulated
radioiodine therapy in patients with MNG. PubMed, Cochrane, CNKI, VIP, and
Wanfang databases were searched. Mean difference (MD) and odds ratios with
95% confidence intervals (95% CI) were derived by using an
inverse variance random-effects model and fixed-effects model, respectively. Six
studies (n=237) were involved in the analysis. For 12 months follow up,
high dose (>0.1 mg) of rhTSH significantly reduced GV
(MD=17.61; 95% CI=12.17 to 23.04; p<0.00001)
compared with placebo. No effective pooled results of low dose of rhTSH
(<0.1 mg) were applicable for only one study included. For 6
months follow up, the source of heterogeneity was determined by subgroup and
sensitivity analysis. High dose group showed vast improvement in GV reduction
(MD=16.62; 95% CI=1.34 to 31.90; p=0.03). The
reduction of low dose group compared with placebo was inferior to high dose
group. No available data were obtained to assess the influence of rhTSH after 36
months follow up for the only included study. Hypothyroidism incidence was
highe...
Source: Hormone and Metabolic Research - Category: Endocrinology Authors: Xu, Chunmei Wang, Ping Miao, Huikai Xie, Tianyue Zhou, Xiaojun Zhang, Qian Jiang, Shan Zhang, Rui Liao, Lin Dong, Jianjun Tags: Endocrine Care Source Type: research
More News: Databases & Libraries | Endocrinology | Hormones | Hypothyroidism | Radioiodine Therapy | Study